Development of an inflammatory tissue-selective chimeric TNF receptor

Chia Jung Lee, Chao Ching Wang, Michael Chen, Kuo Hsiang Chuang, Tian Lu Cheng, Ting Yan Jian, Yun Ming Wang, Tse Hung Huang, Kuang Wen Liao, Shey Cherng Tzou

Research output: Contribution to journalArticle

Abstract

Background: Inhibiting TNF-α is an effective therapy for inflammatory diseases such as rheumatoid arthritis. However, systemic, nondiscriminatory neutralization of TNF-α is associated with considerable adverse effects. Methods: Here, we developed a trimeric chimeric TNF receptor by linking an N-terminal mouse Acrp30 trimerization domain and an MMP-2/9 substrate sequence to the mouse extracellular domain of TNF receptor 2 followed by a C-terminal mouse tetranectin coiled-coil domain (mouse Acrp-MMP-TNFR-Tn). Results: Here, we show that the Acrp30 trimerization domain inhibited the binding activity of TNFR, possibly by closing the binding site of the trimeric receptor. Cleavage of the substrate sequence by MMP-9, an enzyme highly expressed in inflammatory sites, restored the binding activity of the mouse TNF receptor. We also constructed a recombinant human chimeric TNF receptor (human Acrp-MMP-TNFR-Tn) in which an MMP-13 substrate sequence was used to link the human Acrp and the human TNF receptor 2. Human Acrp-MMP-TNFR-Tn showed reduced binding activity, and MMP-13 digestion recovered its binding activity with TNF-α. Conclusion: Acrp-masked chimeric TNF receptors may be able to be used for inflammatory tissue-selective neutralization of TNF-α to reduce the adverse effects associated with systemic neutralization of TNF-α.

Original languageEnglish
Pages (from-to)340-346
Number of pages7
JournalCytokine
Volume113
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Tumor Necrosis Factor Receptors
Matrix Metalloproteinases
Tissue
Substrates
Binding Sites
Digestion
Rheumatoid Arthritis
Enzymes

Keywords

  • Chimeric TNF receptor
  • Inflammation
  • Matrix metalloproteinase (MMP)
  • Tumor necrosis factor-α/receptor (TNF-α/TNFR)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Biochemistry
  • Hematology
  • Molecular Biology

Cite this

Lee, C. J., Wang, C. C., Chen, M., Chuang, K. H., Cheng, T. L., Jian, T. Y., ... Tzou, S. C. (2019). Development of an inflammatory tissue-selective chimeric TNF receptor. Cytokine, 113, 340-346. https://doi.org/10.1016/j.cyto.2018.10.003

Development of an inflammatory tissue-selective chimeric TNF receptor. / Lee, Chia Jung; Wang, Chao Ching; Chen, Michael; Chuang, Kuo Hsiang; Cheng, Tian Lu; Jian, Ting Yan; Wang, Yun Ming; Huang, Tse Hung; Liao, Kuang Wen; Tzou, Shey Cherng.

In: Cytokine, Vol. 113, 01.01.2019, p. 340-346.

Research output: Contribution to journalArticle

Lee, CJ, Wang, CC, Chen, M, Chuang, KH, Cheng, TL, Jian, TY, Wang, YM, Huang, TH, Liao, KW & Tzou, SC 2019, 'Development of an inflammatory tissue-selective chimeric TNF receptor', Cytokine, vol. 113, pp. 340-346. https://doi.org/10.1016/j.cyto.2018.10.003
Lee, Chia Jung ; Wang, Chao Ching ; Chen, Michael ; Chuang, Kuo Hsiang ; Cheng, Tian Lu ; Jian, Ting Yan ; Wang, Yun Ming ; Huang, Tse Hung ; Liao, Kuang Wen ; Tzou, Shey Cherng. / Development of an inflammatory tissue-selective chimeric TNF receptor. In: Cytokine. 2019 ; Vol. 113. pp. 340-346.
@article{949fe4f851404d5c9255260c2369dd6f,
title = "Development of an inflammatory tissue-selective chimeric TNF receptor",
abstract = "Background: Inhibiting TNF-α is an effective therapy for inflammatory diseases such as rheumatoid arthritis. However, systemic, nondiscriminatory neutralization of TNF-α is associated with considerable adverse effects. Methods: Here, we developed a trimeric chimeric TNF receptor by linking an N-terminal mouse Acrp30 trimerization domain and an MMP-2/9 substrate sequence to the mouse extracellular domain of TNF receptor 2 followed by a C-terminal mouse tetranectin coiled-coil domain (mouse Acrp-MMP-TNFR-Tn). Results: Here, we show that the Acrp30 trimerization domain inhibited the binding activity of TNFR, possibly by closing the binding site of the trimeric receptor. Cleavage of the substrate sequence by MMP-9, an enzyme highly expressed in inflammatory sites, restored the binding activity of the mouse TNF receptor. We also constructed a recombinant human chimeric TNF receptor (human Acrp-MMP-TNFR-Tn) in which an MMP-13 substrate sequence was used to link the human Acrp and the human TNF receptor 2. Human Acrp-MMP-TNFR-Tn showed reduced binding activity, and MMP-13 digestion recovered its binding activity with TNF-α. Conclusion: Acrp-masked chimeric TNF receptors may be able to be used for inflammatory tissue-selective neutralization of TNF-α to reduce the adverse effects associated with systemic neutralization of TNF-α.",
keywords = "Chimeric TNF receptor, Inflammation, Matrix metalloproteinase (MMP), Tumor necrosis factor-α/receptor (TNF-α/TNFR)",
author = "Lee, {Chia Jung} and Wang, {Chao Ching} and Michael Chen and Chuang, {Kuo Hsiang} and Cheng, {Tian Lu} and Jian, {Ting Yan} and Wang, {Yun Ming} and Huang, {Tse Hung} and Liao, {Kuang Wen} and Tzou, {Shey Cherng}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.cyto.2018.10.003",
language = "English",
volume = "113",
pages = "340--346",
journal = "Cytokine",
issn = "1043-4666",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Development of an inflammatory tissue-selective chimeric TNF receptor

AU - Lee, Chia Jung

AU - Wang, Chao Ching

AU - Chen, Michael

AU - Chuang, Kuo Hsiang

AU - Cheng, Tian Lu

AU - Jian, Ting Yan

AU - Wang, Yun Ming

AU - Huang, Tse Hung

AU - Liao, Kuang Wen

AU - Tzou, Shey Cherng

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Inhibiting TNF-α is an effective therapy for inflammatory diseases such as rheumatoid arthritis. However, systemic, nondiscriminatory neutralization of TNF-α is associated with considerable adverse effects. Methods: Here, we developed a trimeric chimeric TNF receptor by linking an N-terminal mouse Acrp30 trimerization domain and an MMP-2/9 substrate sequence to the mouse extracellular domain of TNF receptor 2 followed by a C-terminal mouse tetranectin coiled-coil domain (mouse Acrp-MMP-TNFR-Tn). Results: Here, we show that the Acrp30 trimerization domain inhibited the binding activity of TNFR, possibly by closing the binding site of the trimeric receptor. Cleavage of the substrate sequence by MMP-9, an enzyme highly expressed in inflammatory sites, restored the binding activity of the mouse TNF receptor. We also constructed a recombinant human chimeric TNF receptor (human Acrp-MMP-TNFR-Tn) in which an MMP-13 substrate sequence was used to link the human Acrp and the human TNF receptor 2. Human Acrp-MMP-TNFR-Tn showed reduced binding activity, and MMP-13 digestion recovered its binding activity with TNF-α. Conclusion: Acrp-masked chimeric TNF receptors may be able to be used for inflammatory tissue-selective neutralization of TNF-α to reduce the adverse effects associated with systemic neutralization of TNF-α.

AB - Background: Inhibiting TNF-α is an effective therapy for inflammatory diseases such as rheumatoid arthritis. However, systemic, nondiscriminatory neutralization of TNF-α is associated with considerable adverse effects. Methods: Here, we developed a trimeric chimeric TNF receptor by linking an N-terminal mouse Acrp30 trimerization domain and an MMP-2/9 substrate sequence to the mouse extracellular domain of TNF receptor 2 followed by a C-terminal mouse tetranectin coiled-coil domain (mouse Acrp-MMP-TNFR-Tn). Results: Here, we show that the Acrp30 trimerization domain inhibited the binding activity of TNFR, possibly by closing the binding site of the trimeric receptor. Cleavage of the substrate sequence by MMP-9, an enzyme highly expressed in inflammatory sites, restored the binding activity of the mouse TNF receptor. We also constructed a recombinant human chimeric TNF receptor (human Acrp-MMP-TNFR-Tn) in which an MMP-13 substrate sequence was used to link the human Acrp and the human TNF receptor 2. Human Acrp-MMP-TNFR-Tn showed reduced binding activity, and MMP-13 digestion recovered its binding activity with TNF-α. Conclusion: Acrp-masked chimeric TNF receptors may be able to be used for inflammatory tissue-selective neutralization of TNF-α to reduce the adverse effects associated with systemic neutralization of TNF-α.

KW - Chimeric TNF receptor

KW - Inflammation

KW - Matrix metalloproteinase (MMP)

KW - Tumor necrosis factor-α/receptor (TNF-α/TNFR)

UR - http://www.scopus.com/inward/record.url?scp=85055117606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055117606&partnerID=8YFLogxK

U2 - 10.1016/j.cyto.2018.10.003

DO - 10.1016/j.cyto.2018.10.003

M3 - Article

VL - 113

SP - 340

EP - 346

JO - Cytokine

JF - Cytokine

SN - 1043-4666

ER -